哈药股份：GNC中国业务收入纳入哈药股份合并报表

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) is actively working to address its parent company's losses and meet dividend conditions by distributing profits from its subsidiaries, while also focusing on enhancing its market value and operational quality [2] Financial Performance - The revenue from GNC's China operations is included in Harbin Pharmaceutical's consolidated financial statements [2] - The company plans to distribute a total of 404 million yuan (approximately 40.4 million) from its subsidiaries and holding subsidiaries to the parent company for the fiscal years 2023 and 2024 [2] Governance and Management - The company has established a "Market Value Management System" and incorporated market value management into the performance evaluation of senior management [2] - The board of directors and management are committed to maintaining market value and will develop a profit distribution plan in accordance with the Company Law and Articles of Association [2] Strategic Focus - The company aims to enhance its intrinsic value by continuously focusing on its core business and improving operational quality [2] - There is a strong emphasis on protecting shareholder rights as part of the company's strategic initiatives [2]